Company Liminal BioSciences Inc. Nyse
Equities
LMNL
CA53272L2021
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 13/07/08 | |
Director of Finance/CFO | 51 | 01/03/22 | |
Patrick Sartore
PSD | President | 49 | 31/12/05 |
Gary Bridger
CTO | Chief Tech/Sci/R&D Officer | 61 | 30/04/19 |
Director/Board Member | 67 | 13/05/14 | |
Shrinal Inamdar
IRC | Investor Relations Contact | - | - |
Marie Iskra
LAW | General Counsel | 48 | 31/08/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Bridger
CTO | Chief Tech/Sci/R&D Officer | 61 | 30/04/19 |
Director/Board Member | 67 | 13/05/14 | |
Alek Krstajic
CHM | Chairman | 60 | 31/08/20 |
Neil Klompas
BRD | Director/Board Member | 52 | 30/04/19 |
Eugene Siklos
BRD | Director/Board Member | 60 | 31/08/20 |
Director/Board Member | 63 | 30/04/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 3,249,534 | 1,258,903 ( 38.74 %) | 0 | 38.74 % |
Company contact information
Liminal BioSciences, Inc.
440, boulevard Armand-Frappier Suite 300
H7V 4B4, Laval
+450 781 0115
http://www.liminalbiosciences.com![address Liminal BioSciences Inc.(LMNL)](https://cdn.zonebourse.com/static/address/64156495.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+26.71% | 52.73B | |
+37.49% | 39B | |
-9.22% | 38.52B | |
+29.41% | 30.38B | |
-12.26% | 26.39B | |
+10.72% | 26.08B | |
+45.24% | 14.15B | |
+32.44% | 12.6B | |
-5.98% | 11.51B |